Aktienanalyse zu Jaguar Health Inc (JAGX)JAGXJaguar Health Inc

Jaguar Health, Inc. is a commercial stage pharmaceuticals company. The Company is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. It has an exclusive distribution agreement for the sale of Gelclair. It is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Jaguar Health Inc (JAGX) is not a good buy right now. The stock has experienced a staggering 99.92% decline year-to-date and a 75.10% drop over the last five days, indicating severe downward momentum. Additionally, the RSI is at a very low 13.443, suggesting the stock is oversold but may continue to face selling pressure. The forward P/E ratio is extremely high at 200, reflecting uncertainty about future earnings and growth potential. The main risk is the company's negative net income, which was -12,701,000 USD in Q2 2026, indicating ongoing financial challenges that could hinder recovery.

1 analysts cover JAGX: 1 rate it Buy, 0 Hold and 0 Sell.